I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program

Psychological Health/Traumatic Brain Injury Research Program

Complex Traumatic Brain Injury Rehabilitation Research
Clinical Research Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-17-CTRR-CRA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), October 11, 2017
- Invitation to Submit an Application: November 10, 2017
- Application Submission Deadline: 11:59 p.m. ET, December 27, 2017
- End of Application Verification Period: 5:00 p.m. ET, January 3, 2018
- Peer Review: February 2018
- Programmatic Review: April 2018

This Program Announcement must be read in conjunction with the General Application Instructions version 20170516. The General Applications Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ................................................................. 1
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY ................... 3
   II.A. Program Description .................................................................................................. 3
   II.A.1. FY17/18 PH/TBIRP Complex TBI Rehabilitation Research – Clinical Research Award Focus Areas .......................................................... 4
   II.B. Award Information ....................................................................................................... 5
   II.C. Eligibility Information ....................................................................................................... 9
       II.C.1. Eligible Applicants ................................................................................................. 9
       II.C.2. Cost Sharing ........................................................................................................... 9
       II.C.3. Other .................................................................................................................... 10
   II.D. Application and Submission Information .................................................................... 10
       II.D.1. Address to Request Application Package .......................................................... 10
       II.D.2. Content and Form of the Application Submission ................................................ 10
       II.D.3. Dun and Bradstreet Universal Numbering System (DUNS) Number and System for Award Management (SAM) ....................................................... 31
       II.D.4. Submission Dates and Times ............................................................................. 32
       II.D.5. Funding Restrictions ............................................................................................. 32
       II.D.6. Other Submission Requirements .......................................................................... 33
   II.E. Application Review Information .................................................................................. 34
       II.E.1. Criteria ................................................................................................................... 34
       II.E.2. Application Review and Selection Process .............................................................. 37
       II.E.3. Integrity and Performance Information .................................................................. 38
       II.E.4. Anticipated Announcement and Federal Award Dates ........................................ 38
   II.F. Federal Award Administration Information ................................................................. 39
       II.F.1. Federal Award Notices ........................................................................................... 39
       II.F.2. Administrative and National Policy Requirements ................................................ 40
       II.F.3. Reporting ................................................................................................................ 40
   II.G. Federal Awarding Agency Contacts .............................................................................. 41
       II.G.1. CDMRP Help Desk .............................................................................................. 41
       II.G.2. Grants.gov Contact Center .................................................................................. 41
   II.H. Other Information ......................................................................................................... 41
       II.H.1. Program Announcement and General Application Instructions Versions .......... 41
       II.H.2. Administrative Actions ........................................................................................ 41
       II.H.3. Application Submission Checklist ........................................................................ 44
APPENDIX 1: ACRONYM LIST ........................................................................................... 46
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2017/2018 (FY17/18) Psychological Health and Traumatic Brain Injury Research Program (PH/TBIRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs [OASD(HA)], the DHA manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMMP). The execution management agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMMP.

The PH/TBIRP was established by Congress in FY07 in response to the devastating impact of traumatic brain injury (TBI) and psychological health (PH) issues, including post-traumatic stress disorder (PTSD), on our deployed Service members in Iraq and Afghanistan. The PH/TBIRP mission is to establish, fund, and integrate both individual and multiagency research efforts that will lead to improved prevention, detection, and treatment of PH issues and TBI. The vision of the PH/TBIRP is to prevent, mitigate, and treat the effects of traumatic stress and TBI on function, wellness, and overall quality of life for Service members as well as their caregivers and families.

One of six major program areas within the DHA Research and Development Directorate, the JPC-8/CRMMP seeks to implement long-term strategies to develop knowledge and materiel products to reconstruct, rehabilitate, and provide definitive care for injured Service members. The ultimate goal is to return Service members to duty and improve their quality of life. Additional information about the JPC-8/CRMMP can be found at: https://crmrp.amedd.army.mil/.

The PH/TBIRP and JPC-8/CRMMP seek innovative rehabilitation research that has the potential to make a significant impact on improving the health and well-being of military Service members, Veterans, and other individuals with TBI. The programs challenge the clinical and scientific communities to design innovative research that will foster new directions for, and address neglected issues in, the field of TBI rehabilitation research. Applications from investigators within the military Services, and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged.
II.A.1. FY17/18 PH/TBIRP Complex TBI Rehabilitation Research – Clinical Research Award Focus Areas

The FY17/18 PH/TBIRP Complex TBI Rehabilitation Research – Clinical Research Award (CTRR–CRA) is intended to support clinical research focused on understanding the clinical sequelae and mechanisms of recovery associated with TBI and TBI rehabilitation interventions. The overarching goals of this award are to address TBI-related impairments and deficits including sensory, sensorimotor, and cognitive dysfunction to (1) develop and validate rehabilitation outcome measures; (2) define and evaluate mechanisms of injury progression or recovery associated with rehabilitation interventions; and (3) improve clinician-driven assessment strategies to guide return-to-duty decision making.

The FY17/18 PH/TBIRP CTRR–CRA seeks research on the affected patient populations, mechanisms of comorbidities, and potential interventions relevant to TBI rehabilitation and the mission of the JPC-8/CRMRP. To meet the intent of the award mechanism, applications must be responsive to one or both of the following two FY17/18 PH/TBIRP CTRR–CRA Focus Areas:

1. **Mechanisms:** Investigate mechanisms of recovery following isolated or cumulative TBI(s) in Service member-relevant injuries. Investigators should explore at least one of the following:
   - Cognitive Deficits – To inform novel rehabilitation interventions that lead to the recovery of cognitive function.
   - Sensory or Sensorimotor Dysfunction – To inform novel rehabilitation interventions that lead to recovery of sensory or sensorimotor function.

2. **Ecological Assessment:** Develop, evaluate, and/or validate return-to-duty outcome measures following rehabilitation in patients with TBI. Outcome measures may integrate novel or commercially available assessment technologies to enhance measure sensitivity and/or specificity. Priority will be given to outcome measures that are both ecologically valid (i.e., focused on military-specific tasks) and clinically feasible with an aim to inform return-to-duty/participation decisions in either an operational or garrison-based environment. In addition, strong applications will articulate the potential for future impact on return-to-work outcomes in both military and civilian environments. All outcome measures should quantify and characterize patient impairments, functional limitations, and barriers to participation, and the research Project Narrative should have a strong plan for validation in Service member, to include cadet, populations.

**Department of Defense (DoD) and/or VA Collaboration and Alignment Encouraged:**
Relevance to the healthcare needs of the Armed Forces, their family members, and/or the U.S. Veteran population is a key feature of this award. Therefore, Principal Investigators (PIs) are strongly encouraged to collaborate, integrate, and/or align their research projects with military and/or VA research laboratories and programs. The following websites may be useful in identifying information about ongoing DoD and VA areas of research interest:
II.B. Award Information

The anticipated total costs budgeted for the entire period of performance for an FY17/18 PH/TBIRP CTRR–CRA will not exceed $2.0 Million (M). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

The FY17/18 PH/TBIRP CTRR–CRA Program Announcement supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI. PIs should explain how their work will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines.

TBI is defined as being caused by (1) a direct blow or impact to the head, (2) a penetrating head injury, or (3) an exposure to external forces such as blast waves that disrupt the function of the brain. Not all blows to the head or exposure to external forces result in a TBI. The severity of TBI may range from “mild,” a brief change in mental status or consciousness, to “severe,” an extended period of unconsciousness or confusion after the injury. Definitions of TBI severity can be found in Table 1 of the VA/DoD Clinical Practice Guideline for the Management of Concussion–Mild Traumatic Brain Injury.
The FY17/18 PH/TBIRP CTRR–CRA supports clinical research but not clinical trials. Supported research can include observational research studies.

An observational study is a type of clinical study in which individuals are observed or certain outcomes are measured. No attempt is made to affect the outcome. For example, observational studies can include performance-based assessments under resting and physiologically perturbed conditions, such as cardiac stress or cognitive performance tests. These types of studies are not considered clinical trials. For more information on clinical trials and clinical research, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm.

Clinical trials are not supported by this mechanism. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Investigators seeking funding for a clinical trial should apply to the FY17/18 PH/TBIRP CTRR-Clinical Trial Award (W81XWH-17-CTRR-CTA).

Preclinical studies using animals are not supported by this Program Announcement.

Preliminary Data: Applications must include preliminary data and/or published data from the literature that are relevant to complex TBI and support the rationale for the proposed research project.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DoD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO) prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB/EC. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Additional time for regulatory reviews may be needed for clinical studies taking place in international settings. Organizations are encouraged to consider use of site personnel familiar with local/host nation regulatory review requirements. When possible, protocols should be written for research with human subjects and/or human anatomical substances that are specific to the DoD-supported effort outlined in the submitted application. Submission to HRPO of protocols covering more than the scope of work in the DoD-funded award will require HRPO review of the entire protocol as DoD-supported research and may include extensive modifications to meet DoD human subjects protection requirements. Refer to the General Application Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.
If the IRB determines that a study presents greater-than-minimal risk to human subjects, the DoD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, refer to the General Application Instructions, Appendix 1, for more information on study reporting authorities and responsibilities of the research monitor.

**Investigational New Drug/Investigational Device Exemption (IND/IDE):** If the clinical research involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an IND application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required and must be submitted to the FDA prior to the application submission deadline. If the investigational product is a device, evidence that an IDE application that meets all requirements under 21 CFR 812 has been submitted to the FDA prior to the application submission deadline, or that the device is exempt or qualifies for an abbreviated IDE, is required. The Government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA prior to the application submission deadline, or if documented status of the IND or IDE has not been obtained within 6 months of the award date.

**Federal Interagency TBI Research (FITBIR) Informatics System:** For studies that will enroll TBI subjects, the DoD requires that the awardees make data available to the TBI research community by depositing de-identified research data into the FITBIR Informatics System on a quarterly basis. The FITBIR Informatics System is a free resource to the TBI community designed to accelerate comparative effectiveness research on brain injury diagnosis and treatment. Data reporting to FITBIR is an opportunity for investigators to facilitate their own research and collaborate with others doing similar research. While use of the informatics system presents no direct cost to the user, a *project estimation tool* ([https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp](https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp)) is available to help estimate indirect costs and manpower needs associated with data submission.

To contribute to FITBIR, researchers should contact the FITBIR Operations Center ahead of time to arrange for data entry support and to ensure all data have been made compatible with the system. FITBIR guidance and policies, as well as the considerable advantages of FITBIR use to the researcher, are detailed at FITBIR: Federal Interagency Traumatic Brain Injury Research Informatics System ([http://fitbir.nih.gov/](http://fitbir.nih.gov/)).

FITBIR allows for de-identification and storage of data (medical imaging clinical assessment, environmental and behavioral history, etc.) of various types (text, numeric, image, time series, etc.). Use of FITBIR’s Global Unique Identifier (GUID) system facilitates repeated and multi-user access to data without the need to personally identify data sources. FITBIR encourages collaboration between laboratories, as well as interconnectivity with other informatics platforms. Such community-wide sharing requires common data definitions and standards.

Data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI Common Data Elements (CDEs) or entered into the FITBIR data dictionary as new, unique data elements. For the most current version of the NINDS TBI CDEs, go to [http://www.commondataelements.ninds.nih.gov](http://www.commondataelements.ninds.nih.gov). Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs...
collected are compatible with the FITBIR Informatics System. If the proposed research data cannot be entered in CDE format, the investigators must supply a proposal for an alternative data submission or data sharing vehicle and justification for use. Use of the NINDS TBI CDEs is required wherever possible in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical research of TBI.

**TBI Outcomes Reporting:** PIs are highly encouraged to use the Neurobehavioral Symptom Inventory (NSI), a measure of post-TBI symptom severity, and the Patient Global Impression of Change (PGIC), a global outcome measure of patient experience of care. The NSI and PGIC achieved unanimous concurrence by DoD and VA TBI stakeholders in September 2013 as core TBI outcome measures. More information on the NSI and PGIC is available at the respective links below:


**Use of Military and VA Populations or Resources:** If the proposed research involves access to military and/or VA population(s) and/or resource(s), the PI is responsible for establishing access. Access to target military and/or VA patient population(s) or resource(s) should be confirmed at the time of application submission. A letter of support, signed by the lowest-ranking person with approval authority, should be included as part of Attachment 2 for studies involving Service members, Veterans, military and/or VA-controlled study materials, and military and/or VA databases (use Attachment 2: Supporting Documentation to provide this letter). If access cannot be confirmed at the time of application submission, the Government reserves the right to withdraw the application or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resources. Note that access to a Veteran population for clinical studies may only be obtained by (1) collaboration with a VA investigator where the VA investigator has a substantial role in the research or (2) advertising to the general public.

The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.

Awards will be made no later than September 30, 2018, for awards supported with FY17 funds or September 30, 2019, for awards supported with FY18 funds. For additional information refer to Section II.F.1, Federal Award Notices.
II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including international organizations, are eligible to apply.

Government Agencies within the United States: Local, state, and Federal Government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this Program Announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DoD organization. Examples of extramural organizations include academia, biotechnology companies, foundations, Government, and research institutes. Extramural Submission: Application submitted by a non-DoD organization to Grants.gov.

Intramural DoD Organization: A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center. Intramural Submission: Application submitted by a DoD organization for an intramural investigator who is a DoD military or civilian employee working within a DoD laboratory or military treatment facility or in a DoD activity embedded within a civilian medical center.

Note: Applications from an intramural organization or from an extramural non-DoD Federal organization may be submitted through a research foundation.

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator:

Independent investigators at all academic levels (or equivalent) are eligible to submit an application.

An eligible PI regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.
II.C.3. Other

All organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

There are no limitations on the number of applications for which an investigator may be named as a PI.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this Program Announcement.

II.D. Application and Submission Information

*Extramural Submission* is defined as an application submitted by a non-DoD organization to Grants.gov.

*Intramural Submission* is defined as an application submitted by a DoD organization for an intramural investigator, who is a DoD military or civilian employee working within a DoD laboratory or military treatment facility, or working in a DoD activity embedded within a civilian medical center.

II.D.1. Address to Request Application Package

**Submitting Extramural and Intramural Organizations:** Pre-application content and forms can be accessed at eBRAP (https://eBRAP.org).

**Submitting Extramural Organizations:** Full application packages can be accessed at Grants.gov.

**Submitting Intramural Organizations:** Full application packages can be accessed at eBRAP.org.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both *pre-application* and *full application* as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods.

**Pre-Application Submission:** All pre-applications for both extramural and intramural organizations must be submitted through eBRAP (https://eBRAP.org).
eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

**Full Application Submission:** Full applications must be submitted through the online portals as described below.

**Submitting Extramural Organizations:** Full applications from extramural organizations must be submitted through Grants.gov. Applications submitted by extramural organizations (e.g., research foundations) on behalf of intramural DoD or other Federal organizations or investigators will be considered extramural submissions.

**Submitting Intramural DoD Organizations:** Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Intramural DoD organizations that are unable to submit to Grants.gov should submit through eBRAP. Intramural DoD organizations with the capability to submit through Grants.gov may submit following the instructions for extramural submissions through Grants.gov or may submit to eBRAP. Applications from extramural organizations, including non-DoD Federal organizations, received through eBRAP will be withdrawn. See definitions in Section II.C.1, Eligible Applicants.

eBRAP allows intramural organizations to submit full applications following pre-application submission.

**For both Extramural and Intramural submissions:** A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the full application submissions associated with them. eBRAP will validate full application files against the specific Program Announcement requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement.

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application deadline.

**II.D.2.a. Step 1: Pre-Application Submission Content**

During the pre-application process, each submission is assigned a unique log number by eBRAP. This unique eBRAP log number will be needed during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type may result in delays in processing.
If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

- **Tab 2 – Application Contacts**

  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 (R&R) Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 (R&R) Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

  It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

  Enter the name, organization, and role of all collaborators and key personnel associated with the application.

  FY17/18 PH/TBIRP CTRR Programmatic Panel members should not be involved in any pre-application or application. For questions related to Panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

  To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in pre-
application or application preparation, research, or other duties for submitted pre-applications or applications. For FY17, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Pre-applications or applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage conflicts of interest (COIs) are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- **Tab 4 – Conflicts of Interest**

  List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship). Refer to the General Application Instructions, Appendix 3, Section C, for further information regarding COIs.

- **Tab 5 – Pre-Application Files**

  **Note:** Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.

  - **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

    The Preproposal Narrative should include the following:

    - **Rationale:** State the ideas and reasoning on which the proposed clinical research study is based. Briefly describe how the preliminary data and rationale support the research idea. State how this project meets the intent of the award mechanism.

    - **Alignment:** Note specifically which of the FY17/18 PH/TBIRP CTRR–CRA Focus Area(s) the proposed work addresses.

    - **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

    - **Research Strategy:** Clearly describe the clinical research study being proposed. Concisely state the project’s objectives, specific aims, and ultimate endpoints. Briefly describe the proposed recruitment strategies and methods, how they will accomplish the project’s aims, and the outcome measures that will be used.

    - **Research Team:** Provide a description of the research team that clearly demonstrates appropriate background and expertise to accomplish the proposed work.
Impact and Military Benefit: Describe how the proposed work would impact healthcare for military Service members, Veterans, and other individuals recovering from TBI in conjunction with symptoms associated with cognition, sensory, or sensorimotor dysfunction. If applicable, describe how the proposed work will inform return-to-duty decision making.

Estimated total budget.

Pre-Application Supporting Documentation: The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:

- References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

- Key Personnel Biographical Sketches (six-page limit per individual): All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- Quad Chart: Provide a Quad Chart for the proposed project. The Quad Chart template is a one-page PowerPoint file that must be downloaded from eBRAP at https://ebrap.org/eBRAP/public/Program.htm, completed and saved as a PDF file using Adobe Acrobat Reader.

Tab 6 – Submit Pre-Application

This tab must be completed for the pre-application to be accepted and processed.

Pre-Application Screening

Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the JPC-8/CRMRP, pre-applications will be screened based on the following criteria:

- Alignment: How well the project addresses at least one of the FY17/18 PH/TBIRP CTRR-CRA Focus Areas.

- Impact and Military Benefit: To what degree the proposed work would impact healthcare for military Service members, Veterans, and other individuals recovering from TBI in conjunction with symptoms associated with cognition, sensory, or sensorimotor dysfunction. If applicable, to what degree the proposed work will inform return-to-duty decision making.
Objective/Hypothesis and Rationale: How well the objective/hypothesis is stated and supported through preliminary data, scientific rationale, and referenced literature.

Research Strategy: To what degree the rationale, objectives, and specific aims support the research idea. How well the outcome measures and endpoints are defined and are appropriate for the proposed study. Whether the proposed recruitment strategies (if applicable) and methodology are appropriate for accomplishing the research aims.

Research Team: How the qualifications and expertise of the PI and key personnel are appropriate to perform the proposed research.

Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated time frame for notification of invitation to submit an application is indicated in Section I, Overview of the Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

II.D.2.b. Step 2: Full Application Submission Content

Applications will not be accepted unless the PI has received notification of invitation.

All contributors and administrators to the application must use matching compatible versions of Adobe software when editing and preparing application components. The use of different software versions will result in corruption of the submitted file. Refer to the General Application Instructions, Section III, for details on compatible Adobe software.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this Program Announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (http://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations, including non-DoD Federal agencies, must submit full applications through Grants.gov. Submissions of extramural applications through eBRAP may be withdrawn.
Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td><strong>Application Package Location</strong></td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td><strong>Full Application Package Components</strong></td>
</tr>
<tr>
<td><strong>SF424 (R&amp;R) Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; Add Authorized Organizational Representative.</td>
</tr>
</tbody>
</table>
| Descriptions of each required file can be found under Full Application Submission Components:  
  - Attachments  
  - Research & Related Senior/Key Person Profile (Expanded)  
  - Research & Related Budget  
  - Project/Performance Site Location(s) Form  
  - R&R Subaward Budget Attachment(s) Form (if applicable) | Descriptions of each required file can be found under Full Application Submission Components:  
  - Attachments  
  - Key Personnel  
  - Budget  
  - Performance Sites |
| **Application Package Submission** | **Application Package Submission** |
  If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget need to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline. | Submit package components to eBRAP (https://ebrap.org). **Tab 5 – Submit/Request Approval Full Application:** After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller or equivalent Business Official by email to log into eBRAP to review and to approve prior to the application submission deadline. |
<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Verification Period</strong></td>
<td></td>
</tr>
<tr>
<td>The full application package submitted to Grants.gov may be viewed and modified in</td>
<td>After eBRAP has processed the full application, the organizational Resource Manager/</td>
</tr>
<tr>
<td>eBRAP until the end of the application verification period. During the application</td>
<td>Comptroller or equivalent Business Official and PI will receive an email notification</td>
</tr>
<tr>
<td>verification period, the full application package, **with the exception of the Project</td>
<td>of this status and will be able to view and modify application components in eBRAP.</td>
</tr>
<tr>
<td>Narrative and Budget Form**, may be modified.</td>
<td>During the application verification period, the full application package, **with the</td>
</tr>
<tr>
<td></td>
<td><em>exception of the Project Narrative and Budget Form</em>, may be modified.</td>
</tr>
<tr>
<td><strong>Further Information</strong></td>
<td></td>
</tr>
<tr>
<td>Refer to Section III of the General Application Instructions for further information</td>
<td>Refer to Section IV of the General Application Instructions for further information</td>
</tr>
<tr>
<td>regarding Grants.gov requirements.</td>
<td>regarding eBRAP requirements.</td>
</tr>
</tbody>
</table>

*The organization’s Business Official or Authorized Organization Representative (or Resource Manager/Comptroller) should approve/verify the full application submission prior to the application verification deadline.*

Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. *The Project Narrative and Budget cannot be changed after the application submission deadline.* Prior to the full application deadline, a corrected or modified full application package may be submitted. Other application components may be changed until the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

*Material submitted after the end of the application verification period, unless specifically requested by the Government, will not be forwarded for processing.*

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

**II.D.2.b.ii. Full Application Submission Components:**

- **Extramural Applications Only –**

  **SF424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1., for detailed information.
Extramural and Intramural Applications –

Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire full application package may not exceed 200 MB.

Attachment 1: Project Narrative (15-page limit): Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

- **Background:** State the relevance of the research to at least one of the FY17/18 PH/TBIRP CTRR-CRA Focus Areas and explain the applicability of the proposed findings. Present the ideas and reasoning behind the proposed work. Describe previous experience and expertise of the investigators that is most pertinent to this project. Include preliminary and/or published data that are relevant to complex TBI and the proposed research project.

- **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses.

- **Research Strategy:**
  
  - Describe the experimental design, methods, and analyses, including appropriate randomization, blinding, and controls, in sufficient detail for scientific peer review. If any biological material will be used in the proposed studies, the name, definition, pathological classification and source of the material must be provided. Address potential problem areas and present alternative methods and approaches.
  
  - Provide a well-developed, well-integrated research strategy that supports the translational feasibility and promise of the approach detailed in the Transition Plan (Attachment 11: Transition Plan and Regulatory Strategy).
- Define the specific study outcomes and how they will be measured. Describe how data will be collected, handled, and analyzed in a manner that is consistent with the study objectives.

- As applicable, specify and justify the FITBIR Common Data Elements (CDEs) to be used.

- Describe multidisciplinary collaboration, integration, and/or alignment with military and/or VA research laboratories and programs, if applicable.

- As appropriate, include a brief description of the plan for the recruitment of subjects or the acquisition of samples. Full information is provided in Attachment 6: Human Subject Recruitment and Safety Procedures. Specify the approximate number of human subjects to be enrolled. If multiple study sites are to be involved, state the approximate number to be enrolled at each site. Demonstrate that the sample size is appropriate and sufficient to meet the objectives of the study.

  - If human subjects or human anatomical samples will be used, define the target population with regard to injury severity. Refer to the definitions of TBI severity in Table 1 of the VA/DoD Clinical Practice Guideline for the Management of Concussion-Mild Traumatic Brain Injury.

- Statistical Plan and Data Analysis: Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled, if applicable. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.

  - Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf.” Start each document on a new page. If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative. Any additional material viewed as an extension of the Project Narrative will be removed or may result in administrative withdrawal of the application.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested will result in the removal of those items or may result in administrative withdrawal of the application.

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e.,
author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support:** Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration (if applicable):** Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

- **Letters of Commitment (if applicable):** If the proposed study involves use of a commercially produced investigational drug, device, or biologic, provide a letter of commitment from the commercial entity indicating availability of the product for the duration of the study, support for the proposed phase of research, and support for the indication to be tested.

- **Letter(s) of Support for Use of Military and VA Populations or Resources (if applicable):** Provide a letter(s) signed by the lowest-ranking person with approval authority to confirm support for studies involving military Service members, Veterans, military and/or VA-controlled study materials, and military and/or VA databases.

  • Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

– Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community.

  • If applicable, describe the plan to make data available to the TBI research community through the FITBIR Informatics System. If an alternative data sharing vehicle will be employed, provide a justification for its use.

  • Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available. Additionally, the Government reserves the right to identify repositories for submission of data for archive. Any costs associated with submission will be addressed during award negotiations.

– Quad Chart: The Quad Chart template is a one-page PowerPoint file that must be downloaded from eBRAP at https://ebrap.org/eBRAP/public/Program.htm, completed and saved as a PDF file using Adobe Acrobat Reader.

  ○ Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf.” The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Technical abstracts should be written using the outline below. The technical abstract should provide an appropriate description of the project’s key aspects; clarity and completeness within the space limits of the technical abstract are highly important.

  – Background: State how the proposed research addresses one or more of the FY17/18 PH/TBIRP CTRR–CRA Focus Areas. Present the ideas and rationale supporting the proposed research project.

  – Objective/Hypothesis: State the concept/question to be tested. Provide evidence or rationale that supports the objective/hypothesis.

  – Specific Aims: State the specific aims of the study.

  – Study Design: Briefly describe the study design, including appropriate controls.

  – Impact/Military Benefit: Briefly explain how the proposed project will have an immediate or potential long-term impact on the health and well-being of military Service members, Veterans, and other individuals living with complex TBI.
Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf.” The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Minimize use of acronyms and abbreviations, where appropriate. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer community. Do not duplicate the Technical Abstract.

- Describe the objectives and rationale for the application in a manner that will be readily understood by readers without a background in science or medicine.

- Describe the ultimate applicability and potential impact of the research.
  - What types of patients will it help, and how will it help them? Include the current available statistics to the related injury/condition.
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected timeline it may take to achieve the expected patient-related outcome?
  - What are the likely contributions of the proposed research project to advancing the field of complex TBI?

- Briefly describe how the proposed project will benefit military Service members, Veterans, and other individuals living with complex TBI.

Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf.” The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the Clinical Research Award mechanism, use the SOW format example titled “SOW (Statement of Work) Generic Format.” The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:

Include the name(s) of the key personnel and contact information for each study site/subaward site.

Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site.
Refer to Appendix 1 of the General Application Instructions for additional information regarding regulatory requirements.

Briefly state the methods to be used.

For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.

Identify cell line(s) and commercial or organizational source(s) to be used. If human anatomical substances (including cell lines) will be used, specify whether or not identifiable information is accessible to the research team by any means.

If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., IND and IDE applications) by the FDA or other Government agency.

- **Attachment 6: Human Subject Recruitment and Safety Procedures (no page limit): Upload as “HumSubProc.pdf.”** The Human Subject Recruitment and Safety Procedures attachment should include the components listed below, as appropriate.

  - **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Demonstrate that the research team has access to the proposed study population. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical research studies (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays. Include justification of any age, race, ethnicity, or sex limitations provided. *For clinical research studies proposing to include military personnel, refer to the General Application Instructions, Appendix 1, for more information.*

  - **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical research study. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

    - **Inclusion of Women and Minorities in Study:** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the clinical research study.

    - **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).
- Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.

- If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.

- Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

  **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.

  - *For the proposed clinical research study, provide a draft, in English, of the Informed Consent Form.*

  - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the study.

  - Include information regarding the timing and location of the consent process.

  - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.

  - Address how privacy and time for decision making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.

  - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

  - Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical research study to be in compliance with Title 10 United States Code Section 980 (10 USC 980) ([http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf](http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf)). If applicable, refer to the General Application Instructions, Appendix 1, for more information.
- **Assent:** If minors or other populations that cannot provide informed consent are included in the proposed clinical research study, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.

- **Risks/Benefits Assessment:**
  - **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is subjected to as a result of participation in the clinical research study. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

- **Risk management and emergency response:**
  - Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
  - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
  - Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, to include who will be responsible for the cost of such care.
  - Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
  - Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
  - If the IRB determines that a study presents greater-than-minimal risk to human subjects, the DoD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research.
protocol. If applicable, refer to the General Application Instructions, Appendix 1, for more information on study reporting authorities and responsibilities of the research monitor.

- **Potential benefits:** Describe known and potential benefits of the study to the human subject, a specific community, or society.

  - **Attachment 7: Data Management (no page limit):** Upload as “Data_Manage.pdf.” The Data Management attachment should include the components listed below.

    - **Data Management:** Describe all methods used for data collection to include the following:

      - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.

      - **Confidentiality:**

        - Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.

        - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DoD are eligible to review study records.

        - Address requirements for reporting sensitive information to state or local authorities.

      - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. For FDA-regulated studies, compliance with 21 CFR 11 is required.

      - **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

      - **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.
- **Laboratory Evaluations:**

  - **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

  - **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

  - **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

  - **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

- **Attachment 8: Study Personnel and Organization (no page limit):** Start each document on a new page. Combine into one document and upload as “Personnel.pdf.” The Study Personnel and Organization attachment should include the components listed below.

  - **Organizational Chart:** Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers, and/or departments and name each person’s position on the project. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, as appropriate. If applicable, identify the FDA regulatory sponsor and any external consultants or other experts who will assist with FDA applications. While there is no specified format for this information, a table(s) or diagram is recommended.

  - **Study Personnel Description:** Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role. An external research monitor (if applicable) and study coordinator(s) should be included.

  - **Study Management Plan:** Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical research study is multi-institutional, clearly describe the multi-institutional structure governing the research protocol(s) across all participating institutions. Provide a regulatory submission plan for the master protocol and master consent form by the
lead organization; include a single IRB/EC pathway whenever possible. If applicable, describe how communication and data transfer between the collaborating institutions will occur, as well as how data, specimens, and/or imaging products obtained during the study will be handled and shared.

○ **Attachment 9: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit):** Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study. Describe how and when the instrument(s) will be administered. Describe how the instrument(s) will be adapted to the subject population, if applicable.

○ **Attachment 10: Impact and Military Benefit Statement (two-page limit):** Upload as “Impact.pdf.” Describe the short- and long-term impact of this study on the field of complex TBI research, patient care, and/or quality of life, including an assessment of the likelihood that a successful outcome of the proposed research project will lead to a practical application in individuals recovering from military-relevant injuries and diseases incident to military service as well as injuries and diseases occurring in the general public. Address the impact on one or more of the FY17/18 PH/TBIRP CTRR-CRA Focus Areas. Although not all-inclusive, the following are examples of ways in which research projects may have an impact, if successful:

- Describe how the research has the potential to advance the field of complex TBI research.

- Describe how the research contributes to the development or validation of evidence-based policy or guidelines for patient evaluation and care and/or informs return-to-duty decision making.

- Describe any relevant controversies or treatment issues that will be addressed by the proposed research.

- Describe any potential issues that might limit the impact of the proposed research.

- If the active duty military, Veteran, or military family member population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed research, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the results will be relevant to active duty military, Veteran, or military family member population(s).

○ **Attachment 11: Transition Plan and Regulatory Strategy (two-page limit):** Upload as “Transition.pdf.” As applicable, describe/discuss the methods and strategies proposed to move the study to the next phase of development (e.g., clinical practice guidelines [CPGs], clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to
work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below.

- The planned indication for the product label, if appropriate, and an outline of the development plan required to support that indication. Describe in detail the FDA regulatory strategy, to include considerations for compliance with GMP, GLP, and GCP guidelines (if appropriate).

- Details of the funding strategy to transition to the next level of development and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.

- For Knowledge Products, a description of collaborations and other resources that will be used to provide continuity of development including proposed development or modification of CPGs and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications. A “Knowledge Product” is a non-materiel product that addresses an identified need, topic area, or capability gap, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.

- A brief schedule and milestones for transitioning the study to the next phase of development (e.g., clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the FDA).

- Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the Government’s ability to access such products or technologies in the future.

- If applicable, a risk analysis for cost, schedule, manufacturability, and sustainability.

- **Attachment 12: IND/IDE Documentation (no-page limit):** If submitting multiple documents, start each document on a new page. **Combine and upload as a single file named “IND-IDE.pdf.”**

  - Complete the IND/IDE Documentation Form, which is available for download on the Full Announcement page for this Program Announcement on Grants.gov.

  - State whether the study requires regulation by the FDA. If FDA regulation is required, describe the planned indication for the proposed product and whether an IND/IDE is necessary. Identify the IND/IDE sponsor. If an IND or IDE is required,
it must be submitted to the FDA prior to the FY17/18 PH/TBIRP CTRR–CRA application submission deadline.

- If an IND or IDE has already been obtained for the investigational drug or device pertaining to the indication to be studied, provide evidence in the form of formal communication (e.g., letterhead correspondence) from the FDA.

- If an IND or IDE application has been submitted, provide an explanation of the status of the IND or IDE application (e.g., past the critical 30-day period, pending response to questions raised by the Agency, on clinical hold). Provide a summary of previous meetings with the FDA on development of this product, if appropriate. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.

- If an IND or IDE is not required for the proposed study, or if it qualifies for an abbreviated IDE, provide evidence in the form of formal communication (e.g., letterhead correspondence) from the FDA or the IRB of record to that effect. Devices qualifying for an abbreviated IDE must comply with the abbreviated IDE requirements but do not require the submission of an IDE application to the FDA.

- Attachment 13: DoD Military Budget Form(s), if applicable: Upload as “MFBudget.pdf.” If a military facility (military health system facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the DoD Military Budget Form, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs. Refer to the General Application Instructions, Section III.A.7., for detailed information.

- Extramural and Intramural Applications –

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3., and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2., for detailed information.

- PI Biographical Sketch (six-page limit): Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in the portable document format (pdf) that is not editable.

- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
Key Personnel Biographical Sketches (six-page limit each): Upload as “Biosketch_LastName.pdf.”

Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

**Research & Related Budget:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4., and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3., for detailed information.

**Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”** The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

**Project/Performance Site Location(s) Form:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5., and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4., for detailed information.

- **Extramural Applications Only –**

**R&R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section III.A.6., for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.6., for detailed information.)

- **Intramural DoD Collaborator(s):** Complete the DoD Military Budget Form and upload to Grants.gov as Attachment 13. (Refer to the General Application Instructions, Section III.A.7., for detailed information.) Intramural DoD Collaborator(s) costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs.

**II.D.3. Dun and Bradstreet Universal Numbering System (DUNS) Number and System for Award Management (SAM)**

Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant’s organization’s Entity registration in SAM well in advance of the application submission deadline. Allow 3 to 4 weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements by the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant. Refer to Section III of the General Application Instructions for further information regarding Grants.gov requirements.
II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

Prior to the end of the application verification period, PIs and organizational representatives can review and modify in eBRAP certain components of a submitted application. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate retrieved files against the specific Program Announcement requirements and discrepancies will be noted in both the email and in the Full Application Files tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement. *If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline.* The Project Narrative and Budget Form cannot be changed after the application submission deadline.

II.D.5. Funding Restrictions

The maximum period of performance is 4 years.

The anticipated total costs budgeted for the entire period of performance will not exceed **$2.0M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **$2.0M** total costs or using an indirect cost rate exceeding the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

Investigators are encouraged to submit realistic and fully justified budgets and timelines that provide the highest value solution to the Government.

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI to disseminate project results at one In-Progress Review meeting during the period of performance. For planning purposes, it should be assumed that the meeting will be a 1-day meeting held in the National Capital Area in the second year of the award.
• Travel costs for the PI to disseminate project results at one DoD-sponsored scientific meeting (e.g., Military Health System Research Symposium) during the period of performance. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

• Salary
• Research supplies and equipment
• Research-related subject costs
• Clinical research costs (clinical trials are not supported by this Program Announcement)
• Support for multidisciplinary collaborations, including travel
• Travel costs to attend scientific/technical meetings in addition to the required meetings described above

Extramural (non-Federal) awards will consist solely of assistance agreements (Cooperative Agreements and Grants). For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct fund transfer. Intragovernmental only funding to intramural DoD and other Federal agencies will be managed through a direct fund transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.4., for budget regulations and instructions for the Research & Related Budget. For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in Section III.A.4. of the General Application Instructions.

The JPC-8/CRMRP expects to allot approximately $8.0M of the FY17 PH/TBIRP appropriation and $2.0M of the anticipated FY18 PH/TBIRP appropriation to fund approximately 4 Clinical Research Award applications with FY17 funds and approximately 1 award with FY18 funds, depending on the quality and number of applications received. As of the release date of this Program Announcement, the FY18 Defense Appropriations Bill has not been passed and there is no guarantee that any additional funds will be made available to support this program. Funding of applications received in response to this Program Announcement is contingent upon the availability of Federal funds for this program.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.
II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in decreasing order of importance:

- **Research Strategy and Feasibility**
  - How well the preliminary data and scientific rationale supports the research project.
  - To what extent the outcomes will support the translation of promising preclinical findings into a product for clinical application or inform clinical treatment decisions.
  - How well the hypothesis or objective(s) and specific aims are developed.
  - How well the experimental design, methods, data collection procedures, and analyses are developed and support completion of the aims.
  - The degree to which the expected outcomes are specific and measurable.
  - How well the study (or studies) is designed to achieve reproducible and rigorous results, including controls, sample size estimation, blinding, randomization, and data handling.
  - To what extent the proposed research project is feasible as described.
  - How well the application acknowledges potential challenges and addresses alternative strategies.
  - Whether the research can be completed within the proposed period of performance.
  - How well the application addresses the availability of and demonstrates access to human subjects or samples for the proposed research and for research with human subjects, how well the application addresses the prospect of their participation.
  - How well the application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.
  - If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.

- **Impact and Military Benefit**
  - How well the proposed research project addresses one or more of the FY17/18 PH/TBIRP CTRR–CRA Focus Areas.
○ How effective the proposed research project will be in making important contributions toward the goal of advancing complex TBI research and/or patient care.

○ How well the proposed research project addresses a critical problem in complex TBI research, patient care, and/or quality of life.

○ How relevant the anticipated outcomes of the proposed research are to military Service members and Veterans recovering from military-relevant injuries and disease incident to military service.

○ The potential immediate and/or long-term benefits of the proposed research on the health and well-being of Service members, Veterans, and/or their families or communities.

○ If applicable, how well the results of the research will inform return-to-duty decision making for active duty Service members.

• **Transition Plan and Regulatory Strategy**

  ○ How well the application provides sufficient evidence that the research is ready to move into the proposed stage of research.

  ○ How well the project will translate promising, well-founded basic or clinical research findings into clinical applications for individuals living with, or populations at risk for, complex TBI.

  ○ Whether the funding strategy described to bring the outcome(s) to the next level of development and/or delivery to the military or civilian market is appropriate.

  ○ Whether appropriate collaborations and other resources for providing continuity of development are established and/or well described.

  ○ How the schedule and milestones for bringing the outcome(s) to the next level of development are appropriate.

  ○ If applicable, how well the risk analysis for cost, schedule, manufacturability, and sustainability is developed.

  ○ If applicable, how well the application identifies intellectual property ownership, describes an appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any potential impact of intellectual property issues on product development and subsequent Government access to products supported by this Program Announcement.
○ To what degree the regulatory strategy is well-described and feasible, including whether a member of the study team holds the IND/IDE for the indication proposed or whether the timeline proposed for obtaining the IND/IDE, abbreviated IDE, or exemption is appropriate (if applicable).
  – For investigator-sponsored INDs, whether there is evidence of appropriate institutional support, including capabilities to ensure monitoring as required by the FDA.
  – Whether plans to comply with GMP, GLP, and GCP guidelines are appropriate.

• Statistical Plan
  ○ To what degree the statistical model and data analysis plan are suitable for the planned study.
  ○ How the statistical plan, including sample size projections and power analysis, is adequate for the study and all proposed correlative studies.
  ○ Whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

• Personnel
  ○ To what degree the study team’s background and expertise are appropriate to accomplish the proposed work (e.g., experience with military populations and duty requirements, statistical expertise, expertise with TBI, and clinical research studies).
  ○ To what extent the levels of effort by the PI and other key personnel are appropriate to ensure success of this project.
  ○ If applicable, to what extent multidisciplinary collaborations strengthen the proposed research project.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• Budget
  ○ Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement.
  ○ To what degree the budget appropriately accounts and controls for research-specific costs.

• Ethical Considerations
  ○ How the level of risk to human subjects is minimized and how the safety monitoring and reporting plan is appropriate for the level of risk.
○ How well the evidence shows that the procedures are consistent with sound research design and, when appropriate, that these procedures are already in use for diagnostic or treatment purposes.

○ To what degree privacy issues are appropriately considered.

○ To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.

• Environment

○ To what degree the scientific environment, clinical setting, and accessibility of institutional resources support the clinical research study at each participating center or institution (including collaborative arrangements).

○ Whether there is evidence for appropriate institutional commitment from each participating institution.

• Application Presentation

○ To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

• Ratings and evaluations of the peer reviewers

• Relevance to the mission of the DHP, JPC-8/CRMRP, and PH/TBIRP, as evidenced by the following:

  ○ Adherence to the intent of the award mechanism and the FY17/18 PH/TBIRP CTRR-CRA Focus Areas

  ○ Program portfolio composition

  ○ Relative impact and military relevance

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. Each application is evaluated for its own merit, independent of other applications. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, USAMRMC, on behalf of the DHA and the OASD(HA), based on technical merit, the relevance to the mission of the DHP, JPC-8/CRMRP, and PH/TBIRP, the
specific intent of the award mechanism, and to other specified evaluation criteria in the Program Announcement. Programmatic review is a comparison-based process in which applications with scientific and technical merit compete in a common pool. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.shtml.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold (currently $150,000) over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant, at its option, may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about itself that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics and record of performance under Federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoD GAR), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.
II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards will be made no later than September 30, 2018, for awards supported with FY17 funds or September 30, 2019, for awards supported with FY18 funds. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

Awards are made to organizations, not to individual PIs. The types of awards made under the Program Announcement will be assistance agreements (grants or cooperative agreements). The level of involvement on the part of DoD during project performance is the key factor in determining whether to award a grant or cooperative agreement.

**Extramural Organizations:** An assistance agreement (grant or cooperative agreement) is appropriate when the Federal Government transfers a “thing of value,” to a “state, local government,” or “other recipient,” to carry out a public purpose of support or stimulation authorized by a law of the United States, instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement may include collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

After email notification of application review results through the eBRAP, and if selected for funding, a representative from the USAMRAA will contact the business official authorized to negotiate on behalf of the PI’s organization.

Only an appointed USAMRAA Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing documents.

**Intramural Organizations:** Awards to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective resource managers (RM).

After email notification of application review results through the eBRAP, and if selected for funding, a representative from the CDMRP will contact the business official authorized to negotiate on behalf of the PI’s organization.
II.F.1.a. Award Transfers

Unless otherwise restricted, changes in PI will be allowed at the discretion of the USAMRAA Grants Officer, provided that the intent of the award mechanism is met.

The organization transfer of an award supporting a clinical research study is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer. An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

In addition to written progress reports, in-person presentations at the in-progress review meeting may be requested.

Applicable requirements in the DoDGAR found in 32 CFR, Chapter 1, Subchapter C, and 2 CFR Chapter XI, apply to grants and cooperative agreements resulting from this Program Announcement.

Refer to the General Application Instructions, Appendix 2 for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5 for general information regarding national policy requirements.

Refer to full text of the USAMRAA General Research Terms and Conditions for Institutions of Higher Education, Hospitals, and Non-Profit Organizations and the USAMRAA General Research Terms and Conditions with For-Profit Organizations for further information.

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. Annual progress reports as well as a final progress report will be required. Quarterly technical progress reports and quad charts will be required.

Awards resulting from this Program Announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are required to disclose semiannually information about criminal, civil, and administrative proceedings as specified in the applicable Terms and Conditions. The applicable Terms and Conditions for institutions of higher education, hospitals, and nonprofit organizations are
available in OAR Article I, Section B, in the July 2016 R&D General Terms and Conditions. The applicable Terms and Conditions for for-profit organizations are available in Section 34 of the February 2017 USAMRAA General Research Terms and Conditions with For-Profit Organizations.

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to Program Announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

    Phone: 301-682-5507
    Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

    Phone: 800-518-4726; International 1-606-545-5035
    Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this Program Announcement should refer to the Program name, the Program Announcement name, and the Program Announcement version code 20170516c. The Program Announcement numeric version code will match the General Applications Instructions version code 20170516.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:
II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY17/18 PH/TBIRP CTRR Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY17/18 PH/TBIRP CTRR Programmatic Panel members can be found at http://cdmrp.army.mil/phtbi/panels/panels17_crra.
- The application fails to conform to this Program Announcement description to the extent that appropriate review cannot be conducted.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY17/18, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Applications that include
names of personnel from either of these companies will be administratively withdrawn unless plans to manage COIs are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.

- Applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.

- Applications submitted by an intramural DoD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

- The application proposes animal studies.

- The application proposes a clinical trial.

- The application does not demonstrate access to the relevant Military or VA populations or resources.

- For studies requiring an IND or IDE, IND/IDE Documentation (Attachment 12) is missing.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
## II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 (R&amp;R) Application for Federal Assistance (Extramural submissions only)</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (Intramural submissions only)</td>
<td>Complete these tabs as instructed.</td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name “HumSubProc.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 7 with file name “Data_Manage.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Personnel and Organization: Upload as Attachment 8 with file name “Personnel.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveys, Questionnaires, and Other Data Collection Instruments: Upload as Attachment 9 with file name “Surveys.pdf,” if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan and Regulatory Strategy: Upload as Attachment 11 with file name “Transition.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/IDE Documentation: Upload as Attachment 12 with file name “IND-IDE.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DoD Military Budget Form(s): Upload as Attachment 13 with file name “MFBudget.pdf,” if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (Extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Budget (Intramural submissions only)</td>
<td>Complete the DoD Military Budget Form and justification.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R&amp;R Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACURO</td>
<td>Animal Care and Use Review Office</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>COI</td>
<td>Conflict of Interest</td>
</tr>
<tr>
<td>CPG</td>
<td>Clinical Practice Guideline</td>
</tr>
<tr>
<td>CRMRP</td>
<td>Clinical and Rehabilitative Medicine Research Program</td>
</tr>
<tr>
<td>CTRR–CRA</td>
<td>Complex TBI Rehabilitation Research – Clinical Research Award</td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGAR</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FITBIR</td>
<td>Federal Interagency Traumatic Brain Injury Research</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practice</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>GUID</td>
<td>Global Unique Identifier</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
</tr>
<tr>
<td>ICH E6</td>
<td>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</td>
</tr>
<tr>
<td>IDE</td>
<td>Investigational Device Exemption</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>JPC-8</td>
<td>Joint Program Committee-8</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NINDS</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td>NSI</td>
<td>Neurobehavioral Symptom Inventory</td>
</tr>
<tr>
<td>OASD(HA)</td>
<td>Office of the Assistant Secretary of Defense for Health Affairs</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
</tr>
<tr>
<td>PGIC</td>
<td>Patient Global Impression of Change</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PH</td>
<td>Psychological Health</td>
</tr>
<tr>
<td>PTSD</td>
<td>Post-Traumatic Stress Disorder</td>
</tr>
<tr>
<td>PH/TBIRP</td>
<td>Psychological Health and Traumatic Brain Injury Research Program</td>
</tr>
<tr>
<td>RDT&amp;E</td>
<td>Research, Development, Test, and Evaluation</td>
</tr>
<tr>
<td>RM</td>
<td>Resource Manager</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic Brain Injury</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRMC</td>
<td>U.S. Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>U.S. Department of Veterans Affairs</td>
</tr>
</tbody>
</table>